Tamoxifen resistant breast cancer: Coregulators determine the direction of transcription by antagonist-occupied steroid receptors

Journal of Steroid Biochemistry and Molecular Biology

Volumn 69, Issue 1-6, 1999, Pages 45-50

  Takimoto, Glenn S ^a   Graham, J Dinny ^a   Jackson, Twila A ^a   Tung, Lin ^a   Powell, Roger L ^a   Horwitz, Lawrence D ^a   Horwitz, Kathryn B ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; COMPLEMENTARY DNA; DNA; ESTROGEN RECEPTOR; GLUCOCORTICOID RECEPTOR; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; MESSENGER RNA; MIFEPRISTONE; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; ONAPRISTONE; PROGESTERONE RECEPTOR; PROMEGESTONE; PROTEIN; RETINOIC ACID RECEPTOR; STEROID RECEPTOR; TAMOXIFEN; THYROID HORMONE RECEPTOR; VITAMIN D RECEPTOR;

BINDING SITE; BREAST CANCER; CONFERENCE PAPER; DIMERIZATION; DNA BINDING; DRUG RESISTANCE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; NONHUMAN; PHENOTYPE;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; HUMANS; RECEPTORS, STEROID; TAMOXIFEN; TRANSCRIPTION, GENETIC;

EID: 0033050838     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(98)00148-4     Document Type: Conference Paper

References (28)

1. Evans R.M. The steroid and thyroid receptor superfamily. Science. 240:1989;889-895.
2. Mangelsdorf D.J., Thummel C., Beato M., Herrlich P., Schutz G., Umesono K., Blumberg B., Kastner P., Mark M., Chambon P., Evans R.M. The nuclear receptor superfamily: the second decade. Cell. 83:1995;835-839.
3. Horwitz K.B., Jackson T.A., Bain D.L., Richer J.K., Takimoto G.S., Tung L. Nuclear receptor coactivators and corepressors. Mol. Endocrinol. 10:1997;1167-1177.
4. Glass C.K., Rose D.W., Rosenfeld M.G. Nuclear receptor coactivators. Curr. Opinion Cell. Biol. 9:1997;222-232.
5. Onate S.A., Tsai S.Y., Tsai M.-J., O'Malley B.W. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science. 270:1995;1354-1357.
6. Kamei Y., Xu L., Heinzel T., Torchia J., Kurokawa R., Gloss B., Lin S.-C., Heyman R., Rose D.W., Glass C., Rosenfeld M. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell. 85:1996;1-12.
7. Voegel J.J., Heine M.J.S., Zechel C., Chambon P., Gronemeyer H. TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J. 15:1996;3667-3675.
8. Hong H., Kohli K., Trivedi A., Johnson D.L., Stallcup M.R. GRIP1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors. Proc. Natl. Acad. Sci. USA. 93:1996;4948-4952.
9. Cavailles V., Dauvois S., L'Horset F., Lopez G., Hoare S., Kushner P.J., Parker M.G. Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor. EMBO J. 14:1995;3741-3751.
10. Bannister A.J., Kouzarides T. The CBP coactivator is a histone acetyltransferase. Nature. 382:1996;641-643.
11. Spencer T.E., Jenster G., Burcin M.M., Allis C.D., Zhou J., Mizzen C.A., McKenna N.J., Onate S.A., Tsai S.Y., Tsai M.-J., O'Malley B.O. Steroid receptor coactivator-1 is a histone acetyltransferase. Nature. 389:1997;194-198.
12. Beck C.A., Weigel N.L., Moyer M.L., Nordeen S.K., Edwards D.P. The progesterone antagonist RU486 acquires agonist activity upon stimulation of cAMP signaling pathways. Proc. Natl. Acad. Sci. 90:1993;4441-4445.
13. Sartorius C.A., Groshong S.D., Miller L.A., Powell R.L., Tung L., Takimoto G.S., Horwitz K.B. New T47D breast cancer cell lines for the independent study of progesterone B- an A-receptors: only antiprogestin-occupied B-receptors are switched to transcriptional agonists by cAMP. Cancer Res. 54:1994;3868-3877.
14. McDonnell D.P., Clemm D.L., Hermann T, Goldman M.E., Pike J.W. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol. Endocrinol. 9:1995;659-669.
15. Curtis R.E., Boice J., Shriner D.A., Hankey B.F., Fraumeni J.F. Second cancers after adjuvant tamoxifen therapy for breast cancer. J. Natl. Cancer Inst. 88:1996;832.
16. Kedar R.P., Bourne T.H., Powles T.J., Collins W.P., Ashley S.E., Cosgrove D.O., Campbell S. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet. 343:1994;1318-1321.
17. Epstein S., Newcomb P.A., Jordan V.C., Corbone P.P., DeMets D.L. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N. Engl. J. Med. 326:1992;852-856.
18. Bocquel M., Ji J., Ylikomi T., Benhamou B., Vergezac A., Chambon P., Gronemeyer H. Type II antagonists impair the DNA binding of steroid hormone receptors without affecting dimerization. J. Steroid Biochem. Mol. Biol. 45:1993;205-215.
19. Klein-Hitpass L., Cato A.C.B., Henderson D., Ryffel G.V. Two types of antiprogestins identified by their differential action in transcriptionally active extracts from T47D cells. Nucleic Acids Res. 19:1991;1227-1234.
20. Tsurugi K., Collatz E., Wool I.G., Lin A. Isolation of eukaryotic ribosomal proteins. J. Biol. Chem. 251:1976;7940-7946.
21. von Mikecz A.H., Hemmerich P., Peter H.H., Krawinkel U. Characterization of eukaryotic protein L7 as a novel autoantigen which frequently elicits an immune response in patients suffering from systemic autoimmune disease. Immunobiology. 192:1994;137-154.
22. Horlein A.J., Naar A.M., Heinzel T., Torchia J., Gloss B., Kurokawa R., Ryan A., Kamei Y., Soderstrom M., Glass C.K., Rosenfeld M.G. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor corepressor. Nature. 377:1995;397-403.
23. T.A. Jackson, D.L. Bain, K.B. Horwitz ,Antagonist-dependent inhibition by progesterone receptors is mediated by a nuclear repressor? Steroid/thyroid/retinoic acid gene family. Keystone Symposia on Molecular and Cellular Biology, 1996.
24. Jackson T.A., Richer J.K., Bain D.L., Takimoto G.S., Tung L., Horwitz K.B. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Mol. Endocrinol. 11:1997;693-705.
25. Horwitz K.B. Editorial: when tamoxifen turns bad. Endocrinology. 136:1995;821-823.
26. Witte S., Neumann F., Krawinkel U., Przybylski M. Mass spectrometric identification of leucine zipper-like homodimer complexes of the autoantigen L7. J. Biol. Chem. 271:1996;18171-18175.
27. Sartorius C.A., Melville M.Y., Hovland A.R., Tung L., Takimoto G.S., Horwitz K.B. A third transactivation function (AF3) of human progesterone receptors located in the unique N-terminal segment of the B-isoform. Mol. Endocrinol. 8:1994;1347-1360.
28. Chen J.D., Evans R.M. A transcriptional corepressor that interacts with nuclear hormone receptors. Nature. 377:1995;454-457.